or select your discipline:
|
|
|
I hope that 2022 is off to a great start and that, like me, you are anticipating a productive and exciting year ahead in your classrooms, laboratories, clinics, studios, field stations, and more. K-State’s research enterprise continues to make great strides with impressive proposal numbers, including large grants and those involving multiple departments/colleges, a number of new books and other scholarly publications, and increased national and international attention for our groundbreaking discoveries and scholarly insights across every discipline at the university.
This also marks the first full year of our Economic Prosperity Plan, our boldly reaffirmed land grant commitment to driving economic prosperity for Kansans and for Kansas. I look forward to working with many of you in the years ahead to animate this ambitious plan and realize its bold goals. Great research universities seek to translate discovery into impact. Great land grant universities seek to serve and lift their citizens, communities, and state. Kansas State University is both a great research university and one of our nation’s top land grant universities.
Last month I shared the five “We Will” statements created for the OVPR, reaffirming our commitment to serving, enabling, and driving K-State’s research mission.
-
We will seek efficiencies, lower barriers to success, and remove burdens on investigators.
-
We will provide concierge-level service that enables faculty and researcher success.
-
We will be national leaders within our specialties in research administration.
-
We will communicate the value of K-State research to internal and external constituents.
-
We will be an exemplar office on campus for efficiency, effectiveness, integrity, and professionalism.
To that end, and to help us best serve you, we invite you to complete a short survey about this weekly newsletter. Research Weekly aims to provide faculty, staff, and graduate students with information and resources related to research at K-State, but we want to hear from you. What information do you wish was included? What information is the most valuable? Let us know — we value your feedback. Thank you in advance.
Wishing you all a wonderful spring semester and Go ’Cats.
-D. Rosowsky
|
|
Following the completion of the work of the Facilities and Administrative, or F&A, Costs Distribution Task Force in 2020, the Office of the Vice President for Research reviewed the task force recommendations and is moving forward with the adoption of the first option suggested by the group in their March 2021 final report. The new distributions will go into effect with the start of the new fiscal year on July 1, 2022, and will apply to all sponsored projects on the Manhattan campus that generate sponsored research overhead.
The new distributions will be:
|
|
Note that existing projects will have the new distributions applied as of July 1, 2022. Further, the new distributions will no longer assign all of the College share to the college of the lead PI. Distribution among participating colleges and units will follow the credit distribution in the Cayuse record.
|
|
New application, submission process for visiting scholars and non-immigrant employees |
|
The University Research Compliance Office is moving to an online software solution called IRBManager for processing the Export Controls Compliance Review, or ECCR, for visiting scholars and non-immigrant employees. IRBManager is a configurable software system that has allowed K-State’s forms and workflow to be incorporated with virtually no change.
The new system will be easy to use and will make the review process more efficient. Beginning Monday, February 14, the ECCR process will be handled online by IRBManager.
Users will enter information into IRBManager rather than using a fillable PDF. There will be a 30-day grace period for submitting forms using the old PDF file via email to comply@k-state.edu.This grace period will end on March 13, 2022.
|
|
Spring 2022 FDA and USRG Request for Proposals |
|
Deadline: 5 p.m., Monday, March 7
The Office of Research Development announces the Spring 2022 Faculty Development Award, or FDA, and University Small Research Grant, or USRG, call for proposals for Kansas State University tenured or tenure-track faculty who are interested in receiving assistance in their scholarly activities and professional development. Note: faculty must have at least some percentage of their appointment devoted to research.
The Faculty Development Awards program provides support for travel to international meetings — primarily at international locations — or to meet with program officers from potential external sponsors. Due to travel constraints caused by the continuing COVID-19 pandemic, the FDA program will, for the current funding round cover either:
- Registration expenses to present at a virtual professional meeting.
- Travel and registration costs to present at an in-person professional meeting. These awards will be contingent on the in-person meetings occurring as planned with funds not being released until this can be confirmed.
The University Small Research Grants program is a seed grant program to support early research, scholarly activity, and other creative efforts.
If you seek support for travel/projects occurring between July 1, 2022 and December 31, 2022 apply in this competition. For travel/ projects occurring between January 1, 2023 and June 30, 2023, apply in the fall competition, due October 3, 2022
|
|
Q&A: Intro to America’s Seed Fund at NSF |
|
Join this question-and-answer session to learn more about America’s Seed Fund powered by the National Science Foundation. A Small Business Innovation Research/Small Business Technology Transfer, or SBIR/STTR, program director will answer questions about how to get started, the basics of eligibility and what they look for when they review project pitches.
|
|
Equipping academic and corporate researchers for university-industry sponsored research collaboration |
|
10 a.m.
Thursday, Feb. 3
UIDP’s Insights for Researchers Webinar Series provides researchers from both companies and universities with guidance and tools to strengthen sponsored research collaboration. With discussion leaders representing perspectives from both sectors, the series covers essential topics from UIDP’s cornerstone researcher guidance documents, the Researcher Guidebook, and the Researcher Quick Guide.
From tips for establishing initial contacts to budgeting and managing intellectual property, these training sessions build a strong foundation for anyone interested in sponsored research collaboration.
|
|
Noon-1 p.m.
Monday, Feb. 14
Join The National Science Foundation Division of Environmental Biology From noon-1 p.m. on Monday, February 14 for DEB’s next virtual office hour.
Program officers will discuss how to write a great review and answer your questions on any NSF-related topic. To participate, please register.
|
|
NSF Human Networks and Data Science Program Office Hour |
|
Please join the Human Networks and Data Science Program to discuss questions about the program with the program director.
9:30-11 a.m.
Thursday, Feb. 17
9:30-11 a.m.
Thursday, Feb. 24
|
|
Webinar: Funding opportunities with Bayer |
|
8-9 a.m., Noon-1 p.m. or 8-9 p.m.
Tuesday, Feb. 15
Join Halo for a live, interactive webinar with Bayer Crop Science, one of the world’s leading innovators in crop science and pest control.
Bayer scientists will be discussing an innovative new program, Testing4Ag, which will make Bayer's state-of-the-art biological screening cascades available to compounds from labs around the world.
Following a presentation, the Bayer team will answer questions directly from researchers during a live Q&A. You can review the opportunity in advance here.
Who should attend:
- PIs, postdocs and graduate students.
- Startups.
Relevant areas of expertise:
- Plant and crop protection.
- Synthetic and medicinal chemistry.
- Natural product isolation.
Here's what you'll learn:
- Bayer's preferred submissions and how to make your proposal stand out.
- How Bayer can partner to help you bring your innovations to the world.
|
|
Webinar: Funding opportunities with Joyn Bio
|
|
11 a.m.
Wednesday, Feb. 16
Join Halo for an engaging webinar with Joyn Bio, a joint-venture between Ginkgo Bioworks and Leaps by Bayer founded to solve urgent agriculture challenges using the combination of synthetic biology and beneficial microbes.
Joyn Bio scientists will be discussing their funding opportunity on Halo and answering questions directly from researchers. You can review the opportunity in advance here.
Who should attend:
- PIs, Postdocs and PhD Students
- Startups
Relevant areas of expertise:
- Microbiology
- Crop Science
Here's what you'll learn:
- What approaches are of particular interest and what is out of scope
- How proposals will be reviewed and advanced
|
|
1-5 p.m.
Thursday, Feb. 17
Zoom
This training is aimed at informing graduate students, post-docs and early career faculty about various aspects of the grant writing process. Whether you are new to grant writing or have some experience, the information presented will be very relevant and valuable for you. This workshop will include, grant writing orientation, writing the narrative and project summary, budget justification, reviewing criteria and evaluation, and developing your objectives and goals.
|
|
Webinar: Funding opportunities with Sonoco |
|
Noon
Thursday, Feb. 17
Join Halo for a live, interactive webinar with Sonoco, a provider of consumer, industrial, healthcare and protective packaging for many of the world’s most recognized brands across a variety of product segments, including, beverages, snacks, frozen food, and pet care.
Sonoco scientists will be discussing their two funding opportunities on Halo and answering questions directly from researchers. You can review the opportunities in advance here.
Who should attend:
- PIs, postdocs and doctoral students.
- Startups.
Relevant areas of expertise:
- Chemical engineering.
- Materials science.
- Polymer science.
Here's what you'll learn:
- What technologies and approaches are of particular interest.
- What are the must-have versus preferred requirements for a winning solution.
|
|
K-State research in the news |
|
Agency news and trending topics |
|
The NIH continues to support the development of some very innovative therapies to control SARS-CoV-2, the coronavirus that causes COVID-19. One innovative idea involves a molecular decoy to thwart the coronavirus. nih.gov
A drug that blocks danger signals that can lead to harmful inflammation could help reduce COVID-19 lung damage, a new study from NIAID scientists and colleagues has found. Scientists from NIAID’s Rocky Mountain Laboratories in Hamilton, Montana, and the University of Utah completed the project, published online in JCI Insights. nih.gov
In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine. The findings served as the basis for recommendations by the FDA and the Centers for Disease Control and Prevention in late fall 2021 to permit mix-and-match COVID-19 booster vaccinations in the United States. Additional data from the ongoing Phase 1/2 trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are expected in the coming months. nih.gov
Drawing on in-depth interviews with university and industry leaders, the Association of Public and Land-grant Universities today released a report outlining steps universities, industry, and policymakers can take to strengthen collaboration among higher education and industry to advance U.S. innovation and competitiveness. aplu.org
In mid-2021, a handful of meta-analyses looked at the use of ivermectin, a drug to treat people infected with parasitic worms, against COVID-19. The analyses included data suggesting it was effective, which came from clinical trials that almost certainly did not happen as described. (Problems detected in reported trials include copied data, results for patients who died before the trial began, and disputes about whether a trial occurred at all.) nature.com
|
|
k-state.edu/research
researchweekly@k-state.edu
785.532.5110
|
|
|
|
|
|
|
